重组人血管内皮抑制素联合TP化疗治疗晚期卵巢上皮性癌的临床疗效及对免疫功能和预后的影响  

Clinical efficacy of recombinant human endostatin combined TP chemotherapy in advanced ovarian epithelial carcinoma and its effect on immunity and prognosis

作　　者：周晓亮[1] 张晓伟[1] 付改玲[1] ZHOU Xiaoliang;ZHANG Xiaowei;FU Gailing(Department of Gynecology,the First Affiliated Hospital of He’nan University of Science and Technology,Luoyang 471000,He’nan,China)

机构地区：[1]河南科技大学第一附属医院妇科,河南洛阳471000

出　　处：《癌症进展》2021年第22期2347-2350,共4页Oncology Progress

摘　　要：目的探讨重组人血管内皮抑制素(ES)联合顺铂^(+)紫杉醇(TP)化疗治疗晚期卵巢上皮性癌患者的临床疗效及对免疫功能和预后的影响。方法将62例卵巢上皮性癌患者根据治疗方法不同分为对照组(32例,TP方案化疗)和观察组(30例,TP^(+)ES治疗)。对比两组患者临床疗效,治疗前后T细胞(CD3^(+)、CD4^(+)、CD8^(+))、自然杀伤(NK)细胞、免疫蛋白[免疫球蛋白(Ig)A、IgM、IgG]水平及预后情况。结果观察组患者总有效率高于对照组(P﹤0.05)。治疗后,观察组患者T细胞(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、NK细胞及免疫蛋白(IgA、IgM、IgG)水平均升高,对照组患者T细胞(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、NK细胞及免疫蛋白(IgA、IgM、IgG)水平均降低,且观察组患者上述指标均高于对照组,差异均有统计学意义(P﹤0.05)。对照组术后残留病灶﹥2 cm患者比例高于观察组(P﹤0.05)。观察组患者2年生存率及无进展生存率均高于对照组(P﹤0.05)。结论ES联合TP化疗,可提高晚期卵巢上皮性癌患者临床疗效、免疫功能,延长生存时间。Objective To explore the clinical efficacy of recombinant human endostatin(ES)combined carboplatin and paclitaxel(TP)chemotherapy in advanced ovarian epithelial carcinoma and its effect on immunity and prognosis.Method A total of 62 patients with epithelial ovarian cancer were divided into the control group(n=32,treated with TP chemotherapy)and the observation group(n=30,treated with TP^(+)ES)according to different treatments.The clinical effi-cacy,T cell(CD3^(+),CD4^(+),and CD8^(+)),natural killer(NK)cells,immune proteins[immunoglobulin(Ig)A,IgM and IgG]and prognosis between the two groups were compared before and after treatment.Result The total effective rate in the observation group was higher than that in the control group(P<0.05).After treatment,the T cells(CD3^(+),CD4^(+),CD8^(+),and CD4^(+)/CD8^(+)),NK cells and immunoprotein(IgA,IgM,and IgG)in the observation group increased and the control group decreased,with higher indexes in the observation group than those in the control group(P<0.05).The proportion of pa-tients with postoperative residual lesions>2 cm in the control group was higher than that of the observation group(P<0.05).The 2-year survival rate and progression-free survival rate of the observation group were higher than those of the control group(P<0.05).Conclusion ES combined with TP chemotherapy can improve the clinical efficacy and immuni-ty of patients with advanced ovarian epithelial cancer and prolong survival time.

关 键 词：重组人血管内皮抑制素 TP化疗 晚期卵巢上皮性癌 临床疗效 

分 类 号：R737.31[医药卫生—肿瘤]